Session: Who will ensure inclusivity in science and medicine?
Equitable access to medicine has been a long-standing concern within research. While many proposals have been considered to address the issue, none have created long-lasting change. In many ways, new technology is seen as a trusted bridge. Yet, it is only one part of the needed set of actions. This discussion seeks to determine if research has truly entered a “new” era, one where sustainable change is probable. Specifically, it will explore the actions needed to support inclusivity in medicine through the suggested collaboration of industry, health systems, providers and new-tech leaders.
- As to not repeat history what actions are required today
Sanskriti (Sans) Thakur serves the life science industry with executive leadership experience across scientific development, corporate and commercial strategy, with early and large stage companies. Sans is currently the Chief Growth Officer for Medable, the leading SaaS platform for clinical research & development. She is focused on topline & valuation growth to advance the company’s vision of human-centered research, enabling remote access to clinical trials regardless of geography, income, and race. In her journey with Medable she has helped the company grow over 300%, $100M bookings, expansion to 60 countries, and 2.3B in valuation
Beyond her professional titles, she serves with the Global Future Council of the World Economic Forum focusing on data and innovations in healthcare. Sans is a thought leader in issues ranging from modern healthcare, women’s health, clinical trials, to patient advocacy. She is the author of over 18 publications in the areas of science, business, and technology intersections.
Before Medable, Sans served as Head of Global Life Sciences Research for Accenture, responsible for market-shaping strategy and execution of programs in therapeutics, digital health, and scientific innovation across Accenture’s multi- billion-dollar life science enterprise.
During her >20 years in the life sciences industry, Sans has advised more than 30 companies, launched 10 products, advised digital health venture funds, and managed a top 20 pharmaceutical portfolio.